# 50th International GMP Conference Day 1 Recap: AI, Inspections, and the Future of Compliance Source: https://www.globalkeysolutions.net/media/50th-international-gmp-conference-day-1-recap Type: blog Published: March 3, 2026 Updated: March 12, 2026 Authors: George Kwiecinski > GKS recap of Day 1 at the 50th International GMP Conference. Firsthand notes on AI in FDA compliance, 483 guidance, and sterile manufacturing. --- **Event:** [50th International GMP Conference](https://internationalgmp.com/) **Host:** [UGA College of Pharmacy](https://gaiibrs.uga.edu/international-gmp-conference/) **Location:** [Georgia Center for Continuing Education & Hotel](https://www.hotel.uga.edu/events/international-good-manufacturing-practices), Athens, GA **Date:** March 3, 2026 (Day 1) --- GKS was on the ground at the [50th International GMP Conference](https://internationalgmp.com/) hosted by UGA's College of Pharmacy in Athens, Georgia. Co-sponsored by the University of Georgia and the U.S. FDA since 1976, this not-for-profit conference was founded as a neutral forum for FDA and industry to discuss pharmaceutical manufacturing issues, and 50 years later, it remains one of the most important gatherings in GMP. The conference brought together FDA officials, former regulators, pharmaceutical industry leaders, and technology innovators to discuss the intersection of AI, GMP compliance, and the evolving inspection landscape. Here are our firsthand takeaways from Day 1. ![1772653300206.jpg](https://storage.googleapis.com/gks-blog-images/blog-images/70fcb62f423c4144bc252bcc84af16da.jpg) *[George Kwiecinski](https://www.linkedin.com/in/kwiecinskigeorge/) on the ground at the Georgia Center for the 50th International GMP Conference.* ### Full Conference Agenda *50th International GMP Conference, Full Agenda, March 2-5, 2026* ![Masters Hall at the 50th International GMP Conference, UGA Georgia Center](https://storage.googleapis.com/gks-blog-images/blog-images/9c3aad03919c4d4e97edee8956c0181a.jpg) *Masters Hall, Day 1. FDA officials, industry leaders, and compliance professionals gathered at the UGA Georgia Center.* --- ## Morning Session: FDA Drug Inspectorate Updates & Q&A The morning featured presentations from **[Ivy Sweeney](https://www.fda.gov/about-fda/office-human-and-animal-drug-inspectorate-ohadi/ohadi-leadership)** (Acting Office Director of [OHADI](https://www.fda.gov/about-fda/oii-inspectorates/office-human-and-animal-drug-inspectorate-ohadi) within FDA's OII) on Drug Inspectorate updates and **Jessica McAlister** (Olympia Pharmaceuticals) on robust, FDA-ready deviation writing. [GKS](https://www.globalkeysolutions.net) joined for the late-morning Q&A panel, where several key topics were addressed. ### Announced vs. Unannounced Inspections When asked how the FDA decides between announced and unannounced inspections, the panel acknowledged the complexity: - Facilities the FDA has previously visited make unannounced inspections easier to execute - In some cases, the FDA knew inspections were forthcoming for reasons outside the firm's awareness - Foreign inspections add logistical layers (taxis, hotels, coordination) that make unannounced visits abroad more difficult The importance of training investigators to write consistent, high-quality inspection reports was also noted by the panel. This aligns with the broader trend of unannounced foreign inspections that Sweeney and OHADI have been driving. GKS's own research in ["The Foreign Inspection Gap"](https://www.researchgate.net/publication/396808084_The_Foreign_Inspection_Gap_FDA_GMP_Oversightof_US_Drug_Imports_2014-2024) documents how FDA foreign GMP inspections have fallen sharply from 2014 to 2024, underpinning the agency's shift toward surprise visits. ### GMP Certifications When asked whether the FDA would ever issue GMP certifications, the response was vague. No public comment at this time, except stating the obvious: > "At this time, we are not doing that." > - FDA Panel ### FDA Draft Guidance on Responding to 483s The panel confirmed that the FDA's draft guidance for responding to 483 observations is currently under review. The review covers ethics considerations, operational mechanics, and providing firms with a better understanding of what the agency expects. This is a significant development for the industry. The formalization of 483 response expectations could change how firms approach post-inspection corrective action. --- ## Afternoon Session 1: AI in FDA GxP Compliance and Drug Approval **Speaker:** [Howard Sklamberg](https://www.arnoldporter.com/en/people/s/sklamberg-howard), Arnold & Porter Former Deputy Commissioner for Global Regulatory Operations and Policy at FDA, [Sklamberg](https://www.linkedin.com/in/howard-sklamberg-b36977b/) kicked off the afternoon with a wide-ranging session on how AI is reshaping the FDA's regulatory framework, from drug approval to enforcement. ### AI Across the Medical Product Lifecycle The session covered how AI is being applied across every stage of the medical product lifecycle, including FOIA redaction support and compliance monitoring. A key theme: **AI raises GxP compliance expectations**. As the technology becomes more accessible, regulators will expect industry to use it, and to use it responsibly. > "When you're building something new, AI will be built with the new equipment." > - Howard Sklamberg For more on this topic, see his prior discussion of [AI's role in medical products and FDA oversight](https://fdawatch.net/2025/05/01/ai-medical-products-fda-part-2-ai-discovery-design-development/). ### CDER and CBER Guiding Principles A key development: CDER and CBER worked with the European Medicines Agency to develop [10 guiding principles](https://www.fda.gov/about-fda/center-drug-evaluation-and-research-cder/artificial-intelligence-drug-development) for AI/ML in pharmaceutical regulation, a signal that transatlantic regulatory alignment on AI is underway. ### The Cassidy HELP Committee Report The [Cassidy HELP Committee Report](https://www.help.senate.gov/rep/newsroom/press/chairman-cassidy-releases-landmark-report-to-modernize-fda-deliver-lifesaving-affordable-treatments-to-american-families) ("Patients and Families First: Building the FDA of the Future") was also referenced, underscoring Congressional interest in how FDA is handling AI adoption in drug regulation. ### Common Regulatory Challenges When AI Is Used A particularly relevant slide outlined the **common regulatory challenges when AI is used in GxP environments**, covering validation, transparency, change control, and the auditability of AI-driven decisions. ### Inspections & Enforcement: Practical Implications The session included real-world enforcement examples where AI intersected with compliance failures, reinforcing that **the inspection landscape is already adapting to AI-augmented processes**. For further context, see his commentary on [FDA inspectorate reorganization](https://www.arnoldporter.com/en/perspectives/media-mentions/2025/10/pink-sheet-interviews-howard-sklamberg) and [pOAI designations](https://www.arnoldporter.com/en/perspectives/media-mentions/2026/03/howard-sklamberg-quoted-in-pink-sheet) for additional perspective on the enforcement direction discussed. --- ## Afternoon Session 2: "Lawyers, Guns and Money": Non-Compliance Beyond 483s and Warning Letters **Speaker:** [Alan Minsk](https://www.agg.com/professionals/alan-minsk/), Arnall Golden Gregory (AGG) [Minsk](https://www.linkedin.com/in/alan-minsk-9269792/), partner and leader of AGG's Food & Drug team, titled his presentation *"Lawyers, Guns and Money,"* driving home a fundamental point: **compliance is required by law**. He explored the broader consequences firms face beyond FDA observations, including DOJ referrals, consent decrees, and corporate integrity agreements. Minsk has [written on the topic of ignoring FDA during inspections](https://www.agg.com/news-insights/publications/theres-no-reply-at-all-its-never-a-good-idea-to-ignore-fda-during-an-inspection-and-in-fact-its-illegal/) and [handling regulatory meetings](https://www.agg.com/news-insights/publications/honesty-is-hardly-ever-heard-and-mostly-what-fda-needs-from-your-firm-handling-a-regulatory-call-or-meeting-with-fda/), making him one of the leading voices on practical enforcement risk. ### Q&A Highlights (Sklamberg & Minsk Joint Panel) **Q (asked by GKS): Is there precedent for FOIA-requesting AI and FDA chats?** **GKS posed this question directly to the panel**, given the growing use of AI chat interfaces within federal agencies and the open question of whether those interactions constitute agency records subject to FOIA disclosure. The panel noted that any written document in FDA custody could be subject to FOIA disclosure, with appropriate redactions. **On auto-transcription risks:** One point that came up was the compliance risk of auto-transcription tools in corporate settings. The issue isn't that people say things they shouldn't. It's that auto-transcription captures everything indiscriminately, and most people don't realize the transcript is running, much less that it's discoverable. Word-for-word transcripts of internal meetings can be FOIA'd, subpoenaed, or surfaced in discovery. **Takeaway:** Firms should have clear policies about when transcription is on, who controls it, and how those records are managed. Awareness is the first step. --- ## Afternoon Session 3: The Augmented Auditor: AI as a Catalyst for Better Compliance **Speaker:** [Sarah Barkow, PhD](https://www.pda.org/global-event-calendar/conferences/speaker/sarah-barkow-phd-1823369), AstraZeneca [Barkow](https://www.linkedin.com/in/sbarkow/), Senior Director of Proactive Compliance & Innovation at AstraZeneca and co-lead author on the [FDA draft guidance on Data Integrity and Compliance With CGMPs](https://rx-360.org/wp-content/uploads/2018/08/Sarah-Barkow_ISPE-2016.pdf), delivered one of the most forward-looking sessions of the day. ### Why AI? Why Now? The session contextualized the AI push within the current regulatory landscape, referencing the **PIC/S and Eudralex Draft Annex 22 on Artificial Intelligence** as emerging frameworks that will shape how AI is governed in GMP environments. AstraZeneca's own [AI ethics and governance framework](https://www.astrazeneca.com/content/astraz/sustainability/ethics-compliance/data-and-ai-ethics.html) provides a model for how large pharma companies are approaching responsible AI adoption. ### How AI Augments, Not Replaces, Auditors The core thesis: AI handles data-heavy pattern recognition (deviation trend analysis, regulatory intelligence, document comparison) while human auditors focus on judgment, context, and relationship-based assessment. > "You don't want a regulator to come in, look at your deviations, and find trends you had not." > - Sarah Barkow This point is especially relevant to the quality unit. Teams must be both trained and situationally aware of what trends exist in their own data. If AI can surface a pattern that your quality team missed, regulators will question whether the quality unit was adequately informed and empowered to act. ### Synthetic Deviation Analysis The session demonstrated a synthetic deviation analysis workflow, using AI to surface patterns across deviation records that human reviewers might miss due to volume or inconsistent language. Tabular outputs and structured summaries make the analysis actionable. ### Document Comparison & Regulatory Intelligence AI-driven document comparison was another key use case, critical for firms managing regulatory submissions across jurisdictions. AI-assisted translation and comparison tools dramatically reduce timelines that previously took weeks. ### Warning Letters as a Teaching Tool > "One of the great values of FDA warning letters is as a teaching tool. You can use things like FDA observations to build it out." > - Sarah Barkow This aligns directly with GKS's approach through **[KeyPedia](https://www.globalkeysolutions.net/keypedia-light)**, using [FDA warning letter data](https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters) as a foundation for proactive compliance intelligence. ### Aspirational AI The session closed with a vision for aspirational AI in quality: heat maps, trend dashboards, and predictive compliance tools that shift the quality function from reactive to proactive. --- ## Afternoon Session 4: No Barriers to Success: Modern Technology in Sterile Filling Operations **Speaker:** Erika Pfeiler, Valsource The final speaker session was a deep dive into sterile drug manufacturing technology, specifically the evolution from open processing to modern barrier systems. ### The Evolution of Sterile Manufacturing The session traced the history of sterile manufacturing GMPs: - **1978 GMPs:** Basic cleanroom definitions, no mention of barrier systems - **2004:** Introduction of isolator guidance - **Today:** RABS (Restricted Access Barrier Systems) and isolators are standard ### RABS and Isolators The session explored the different types of barrier systems, their regulatory considerations, and common pitfalls during inspections. ### Contamination Control Strategy The session covered contamination control strategy requirements, first air principles, and the role of **vaporized hydrogen peroxide (VHP)** in modern aseptic processing, including a notable exchange about whether VHP should be classified as a sterilant (see Q&A below). ### PDA Points to Consider Pfeiler referenced PDA's *Points to Consider for Isolators* as a key industry resource. --- ## Q&A Panel: Closing Discussion ### Third-Party Auditors and AI Data Privacy The panel acknowledged that auditors and third parties need to maintain confidentiality, but noted that **most people are currently using public models**, raising data security concerns. The panel also observed that very few contract auditors are currently equipped to handle these questions, making vendor due diligence on AI usage an emerging requirement. ### VHP as a Sterilant A pointed question challenged Pfeiler's characterization of VHP: This sparked a nuanced technical exchange about center-specific guidance differences, a reminder that CDER and CDRH don't always align on terminology, and firms working across drug and device product lines need to track both. ![50th International GMP Conference materials and presentation, UGA Georgia Center](https://storage.googleapis.com/gks-blog-images/blog-images/ab899dbbdf8f48a3b2a509fd35afbfd5.jpg) *Conference materials at the 50th International GMP Conference. Already looking ahead to the 51st in March 2027.* --- ## Dinner Keynote: Extreme Weather and the Drug Supply Chain **Speaker:** [Dr. Marshall Shepherd](https://geography.uga.edu/directory/people/j-marshall-shepherd), UGA Franklin College of Arts and Sciences The day closed with a dinner keynote from Dr. Marshall Shepherd on extreme and compound weather events. Whether it's forest fire smoke and earthquakes out West, tornadoes across the Plains, hurricanes and snowstorms in the Southeast and Northeast, or extreme events globally, we are all subject to the weather. Dr. Shepherd spoke about his distinguished efforts in atmospheric science and tied it back perfectly into quality and regulatory. We are responsible for the drug supply chain, and weather is not something to ignore, especially with increasing extremes and variance in storms. Beyond imports and ports, his message pushed the audience to think critically about where we source materials and build manufacturing infrastructure. A fitting close to a day focused on compliance and preparedness: supply chain resilience extends well beyond regulatory risk. --- ## GKS Takeaways from Day 1 2. **483 response guidance is coming.** The FDA's draft guidance for responding to 483 observations is under review and will formalize expectations 3. **Auto-transcription is a compliance risk.** Word-for-word transcripts are discoverable; firms need clear policies on when, how, and what gets recorded 4. **AI augments, it doesn't replace.** The auditor's role evolves but remains essential; AI handles pattern recognition while humans handle judgment 5. **Deviation trend analysis is table stakes.** If AI can find your trends before you do, regulators will ask why you didn't --- *Stay tuned for our Day 2 and Day 3 recaps from the [50th International GMP Conference](https://internationalgmp.com/).* **Want deviation trend analysis powered by 1.5M+ FDA data points?** [Try KeyPedia Light](https://www.globalkeysolutions.net/keypedia-light) or [schedule a demo](https://www.globalkeysolutions.net/schedule-demo). **Read our research:** - [An Analysis of FDA Warning Letter Citations from 2019-2023](https://doi.org/10.1007/s12247-024-09879-x), *J. Pharm. Innov.* (2024) - [The Foreign Inspection Gap: FDA GMP Oversight of U.S. Drug Imports, 2014-2024](https://doi.org/10.21203/rs.3.rs-7849765/v1), Research Square (2025) For more information or questions, reach us at [gk@globalkeysolutions.net](mailto:gk@globalkeysolutions.net). *GKS was present at the 50th International GMP Conference, March 2-5, 2026, Athens, GA.*